EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cefiderocol nonsusceptibility among carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii : data from the 2024 Antimicrobial Testing Leadership and Surveillance (ATLAS) program

Po-Wei Chiu, Jiun-Ling Wang iD, Shun-Chung Hsueh, Nan-Yao Lee, Yu-Tsung Huang, Wen-Chien Ko, Po-Ren Hsueh iD

Antimicrobial Agents and Chemotherapy · 05.08.2026 · 70 (8)

DOI: 10.1128/aac.00634-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 05.08.2026. Verfasst von Po-Wei Chiu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Cephalosporins, Anti-Bacterial Agents, Carbapenems. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We evaluated cefiderocol activity against carbapenem-resistant Pseudomonas aeruginosa (CRPA) and carbapenem-resistant Acinetobacter baumannii (CRAB), characterized the β-lactamase gene profiles of cefiderocol-nonsusceptible CRPA by metallo-β-lactamase (MBL) subtype, and assessed cross-resistance with comparator agents. Cefiderocol minimum inhibitory concentrations (MICs) for 890 CRPA and 1,063 CRAB isolates from the 2024 Antimicrobial Testing Leadership and Surveillance (ATLAS) program were determined by broth microdilution using iron-depleted cation-adjusted Mueller-Hinton broth. Cefiderocol nonsusceptibility was defined as MIC ≥ 8 mg/L per CLSI (intermediate + resistant). DTRPA was defined as nonsusceptible to all anti-pseudomonal β-lactams and fluoroquinolones; DTRAB was defined as nonsusceptible to carbapenems, ampicillin-sulbactam, and fluoroquinolones, reflecting species-specific susceptibility panels. CRPA isolates underwent molecular screening for bla NDM , bla VIM , bla IMP , serine carbapenemase, and ESBL genes; genotype data were not available for A. baumannii . Cefiderocol susceptibility was 93.9% for CRPA and 88.5% for CRAB, respectively (nonsusceptibility 6.1% and 11.5%, respectively; OR = 2.01, P < 0.001); nonsusceptibility among DTRPA and DTRAB was 8.1% and 11.7%, respectively. Among 54 cefiderocol-nonsusceptible CRPA, 41 (76%) harbored no detectable carbapenemase gene. Nonsusceptibility among MBL-positive CRPA was exclusively attributable to bla NDM producers (27.7%, 13/47); bla VIM -positive ( n = 68) and bla IMP -positive ( n = 21) isolates were uniformly susceptible. Among cefiderocol-nonsusceptible CRPA, 98.1% were co-resistant to ceftazidime-avibactam and 96.3% to ceftolozane-tazobactam.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acinetobacter baumanniiCephalosporinsAnti-Bacterial AgentsCarbapenemsPseudomonas aeruginosaCefiderocolMicrobial Sensitivity Testsbeta-LactamasesHumansCeftazidimeDrug Resistance, Multiple, BacterialDrug CombinationsAzabicyclo Compounds

Stichwörter der Autor:innen

Antimicrobial Testing Leadership and Surveillance programcarbapenem-resistant Acinetobacter baumanniicarbapenem-resistant Pseudomonas aeruginosacefiderocol nonsusceptibilitymetallo-β-lactamase

Substanzen

CefiderocolCephalosporinsAnti-Bacterial AgentsCarbapenemsbeta-LactamasesCeftazidimeavibactam, ceftazidime drug combinationDrug CombinationsAzabicyclo Compounds

Autor:innen und Institutionen

  • Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
  • Department of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan.
  • Center for Infection Control, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei City, Taiwan.
  • Division of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, School of Medicine, China Medical University, Taichung, Taiwan.

ORCID-Profile: Jiun-Ling Wang, Po-Ren Hsueh

Zitieren

APA

Chiu, P. W., Wang, J. L., Hsueh, S. C., Lee, N. Y., Huang, Y. T., Ko, W. C., & Hsueh, P. R. (2026). Cefiderocol nonsusceptibility among carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii : data from the 2024 Antimicrobial Testing Leadership and Surveillance (ATLAS) program. Antimicrobial Agents and Chemotherapy, 70(8). https://doi.org/10.1128/aac.00634-26

Vancouver

Chiu PW, Wang JL, Hsueh SC, Lee NY, Huang YT, Ko WC, et al. Cefiderocol nonsusceptibility among carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii : data from the 2024 Antimicrobial Testing Leadership and Surveillance (ATLAS) program. Antimicrobial Agents and Chemotherapy. 2026;70(8). doi:10.1128/aac.00634-26

BibTeX
@article{Chiu2026,
  author = {Chiu, Po-Wei and Wang, Jiun-Ling and Hsueh, Shun-Chung and Lee, Nan-Yao and Huang, Yu-Tsung and Ko, Wen-Chien and Hsueh, Po-Ren},
  title = {Cefiderocol nonsusceptibility among carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii : data from the 2024 Antimicrobial Testing Leadership and Surveillance (ATLAS) program},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {8},
  doi = {10.1128/aac.00634-26}
}
Kostenlos starten →